A practical "ABCDE" approach to the metabolic syndrome.

The metabolic syndrome comprises a cluster of risk factors for cardiovascular disease and type 2 diabetes mellitus that are due to abdominal obesity and insulin resistance. This increasingly important proinflammatory condition remains both underrecognized and undertreated. To aid physicians in their approach to the metabolic syndrome, we assessed and synthesized the literature on cardiovascular risk assessment and early intervention for risk reduction. We performed a comprehensive search of MEDLINE and the Cochrane database for peer-reviewed clinical studies published from January 1, 1988, to December 31, 2007, augmented by consultation with content experts. We used the search terms metabolic syndrome, abdominal obesity, waist circumference, insulin resistance, cardiovascular disease, prediabetes, diabetes, treatment, prevention, aspirin, hypertension, cholesterol, atherogenic dyslipidemia, lifestyle therapy, diet, and exercise. Criteria used for study review were controlled study design, English language, relevance to clinicians, and validity based on experimental design and appropriateness of conclusions. Although growing evidence supports early intervention in patients with the metabolic syndrome, many physicians do not recognize the risk associated with this condition and fail to initiate early treatment. A comprehensive management plan can be assembled through an "ABCDE" approach: "A" for assessment of cardiovascular risk and aspirin therapy, "B" for blood pressure control, "C" for cholesterol management, "D" for diabetes prevention and diet therapy, and "E" for exercise therapy. This ABCDE approach provides a practical and systematic framework for encouraging metabolic syndrome recognition and for implementing a comprehensive, evidence-based management plan for the reduction of cardiovascular risk.

[1]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[2]  V. Somers,et al.  The apolipoprotein b/apolipoprotein AI ratio in the metabolic syndrome-should we start using it? , 2008, Journal of the cardiometabolic syndrome.

[3]  M. Martínez-González,et al.  Mediterranean Diet Inversely Associated With the Incidence of Metabolic Syndrome , 2007, Diabetes Care.

[4]  Deepak L. Bhatt,et al.  Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. , 2008, JAMA.

[5]  E. Tuzcu,et al.  Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. , 2008, JAMA.

[6]  J. O’Keefe,et al.  Omega-3 fatty acids for cardioprotection. , 2008, Mayo Clinic proceedings.

[7]  J. Després,et al.  Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients , 2008, Diabetes Care.

[8]  I. Olkin,et al.  Using pedometers to increase physical activity and improve health: a systematic review. , 2007, JAMA.

[9]  M. Martínez-González,et al.  Mediterranean Diet Inversely Associated With the Incidence of Metabolic Syndrome , 2007, Diabetes Care.

[10]  L. Barouch,et al.  Leptin signaling and obesity: cardiovascular consequences. , 2007, Circulation research.

[11]  A. Lincoff,et al.  Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. , 2007, JAMA.

[12]  M. Hanefeld,et al.  Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. , 2007, The New England journal of medicine.

[13]  F. Hu,et al.  Diet and cardiovascular disease prevention the need for a paradigm shift. , 2007, Journal of the American College of Cardiology.

[14]  Lawrence A Leiter,et al.  Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. , 2007, The American journal of cardiology.

[15]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[16]  R. Blumenthal,et al.  Metabolic syndrome is associated with coronary artery calcium in asymptomatic white Brazilian men considered low-risk by Framingham risk score. , 2007, Preventive cardiology.

[17]  G. Reaven The Individual Components of the Metabolic Syndrome: Is There a Raison d'Etre? , 2007, Journal of the American College of Nutrition.

[18]  J. Murabito,et al.  Prevalence and Prognostic Impact of Subclinical Cardiovascular Disease in Individuals With the Metabolic Syndrome and Diabetes , 2007, Diabetes.

[19]  T. Hansen,et al.  Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. , 2007, Journal of the American College of Cardiology.

[20]  Bernard J. Gersh,et al.  Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention , 2007, Circulation.

[21]  I. Lee Dose-response relation between physical activity and fitness: even a little is good; more is better. , 2007, JAMA.

[22]  C. Ebbeling,et al.  Effects of a low-glycemic load vs low-fat diet in obese young adults: a randomized trial. , 2007, JAMA.

[23]  S. Blair,et al.  Effects of different doses of physical activity on cardiorespiratory fitness among sedentary, overweight or obese postmenopausal women with elevated blood pressure: a randomized controlled trial. , 2007, JAMA.

[24]  Susan Smyth,et al.  Aspirin dose for the prevention of cardiovascular disease: a systematic review. , 2007, JAMA.

[25]  H. Tsutsui [Candesartan in heart failure: assessment of reduction in mortality and morbidity]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.

[26]  R. Kahn Metabolic Syndrome: Is It a Syndrome? Does It Matter? , 2007, Circulation.

[27]  B. Balkau Does diagnosis of the metabolic syndrome detect further men at high risk of cardiovascular death beyond those identified by a conventional cardiovascular risk score? The DECODE Study: The Diabetes Epidemiology: Collaborative analysis Of Diagnostic Criteria in Europe (DECODE) Study Group , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[28]  Y. Matsuzawa,et al.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.

[29]  Rowena J Dolor,et al.  Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. , 2007, Journal of the American College of Cardiology.

[30]  D. Grobbee,et al.  High dietary glycemic load and glycemic index increase risk of cardiovascular disease among middle-aged women: a population-based follow-up study. , 2007, Journal of the American College of Cardiology.

[31]  J. LeLorier,et al.  Effect of ramipril on the incidence of diabetes. , 2007, The New England journal of medicine.

[32]  Victor M Montori,et al.  Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. , 2007, Journal of the American College of Cardiology.

[33]  J. Danesh,et al.  Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies , 2007, Circulation.

[34]  Chaoyang Li,et al.  Increasing Trends in Waist Circumference and Abdominal Obesity among U.S. Adults , 2007, Obesity.

[35]  R. Weinstock,et al.  The metabolic syndrome: concepts and controversy. , 2006, Mayo Clinic proceedings.

[36]  A. Kong,et al.  The role of adipocytokines and neurohormonal dysregulation in metabolic syndrome. , 2006, Current diabetes reviews.

[37]  M. Laakso,et al.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.

[38]  Antonio Ceriello,et al.  The effects of diet on inflammation: emphasis on the metabolic syndrome. , 2006, Journal of the American College of Cardiology.

[39]  M. Blaha,et al.  Clinical Use of the Metabolic Syndrome: Why the Confusion? , 2006 .

[40]  S. Grundy Does the Metabolic Syndrome Exist? A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. , 2006, Diabetes Care.

[41]  G. Mancia,et al.  Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial , 2006, Journal of hypertension.

[42]  Susan Mayor,et al.  NICE removes β blockers as first line treatment for hypertension , 2006, BMJ : British Medical Journal.

[43]  S. Grundy,et al.  Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. , 2006, Journal of the American College of Cardiology.

[44]  T. Buchanan,et al.  Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. , 2006, Diabetes.

[45]  D. Cota,et al.  The emerging role of the endocannabinoid system in endocrine regulation and energy balance. , 2006, Endocrine reviews.

[46]  S. R. Ferreira,et al.  The new adipose tissue and adipocytokines. , 2006, Current diabetes reviews.

[47]  M. Davidson Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions , 2006, Expert opinion on drug safety.

[48]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[49]  S. Grundy,et al.  Does the metabolic syndrome exist. Authors' reply , 2006 .

[50]  T. Rowland Aerobic Exercise Training Improves Insulin Sensitivity Without Changes in Body Weight, Body Fat, Adiponectin, and Inflammatory Markers in Overweight and Obese Girls , 2006 .

[51]  Richard W Morris,et al.  Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. , 2005, Archives of internal medicine.

[52]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[53]  R. D'Agostino,et al.  Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus , 2005, Circulation.

[54]  G. Nassis,et al.  Aerobic exercise training improves insulin sensitivity without changes in body weight, body fat, adiponectin, and inflammatory markers in overweight and obese girls. , 2005, Metabolism: clinical and experimental.

[55]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.

[56]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[57]  J. Kampert,et al.  Cardiorespiratory Fitness Is Inversely Associated With the Incidence of Metabolic Syndrome: A Prospective Study of Men and Women , 2005, Circulation.

[58]  N. Cook,et al.  Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. , 2005, JAMA.

[59]  M. Pfeffer,et al.  Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure , 2005, Circulation.

[60]  E. Ford Rarer than a blue moon: the use of a diagnostic code for the metabolic syndrome in the U.S. , 2005, Diabetes care.

[61]  F. Clavel-Chapelon,et al.  Modified Mediterranean diet and survival: EPIC-elderly prospective cohort study , 2005, BMJ : British Medical Journal.

[62]  A. Aljada,et al.  Contemporary Reviews in Cardiovascular Medicine Metabolic Syndrome A Comprehensive Perspective Based on Interactions Between Obesity, Diabetes, and Inflammation , 2022 .

[63]  C. Lavie,et al.  Cardiac rehabilitation and exercise training programs in metabolic syndrome and diabetes. , 2005, Journal of cardiopulmonary rehabilitation.

[64]  Stephen W. Sorensen,et al.  The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance , 2005, Annals of Internal Medicine.

[65]  S. Grundy,et al.  Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). , 2005, The American journal of cardiology.

[66]  Maria Inês Schmidt,et al.  The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. , 2005, Diabetes care.

[67]  R. Blumenthal,et al.  A simplified approach to the management of non-ST-segment elevation acute coronary syndromes. , 2005, JAMA.

[68]  L. Bielak,et al.  Association between metabolic syndrome and subclinical coronary atherosclerosis in asymptomatic adults. , 2004, The American journal of cardiology.

[69]  Jeannie K. Lee,et al.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins , 2004, Circulation.

[70]  S. Haffner,et al.  Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? , 2004, Diabetes care.

[71]  E. Ford,et al.  Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. , 2004, Archives of internal medicine.

[72]  Ali H Mokdad,et al.  Increasing prevalence of the metabolic syndrome among u.s. Adults. , 2004, Diabetes care.

[73]  R. Marfella,et al.  Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. , 2004, JAMA.

[74]  R. Blumenthal,et al.  A practical and evidence-based approach to cardiovascular disease risk reduction. , 2004, Archives of internal medicine.

[75]  David C Parish,et al.  Abdominal adiposity in U.S. adults: prevalence and trends, 1960-2000. , 2004, Preventive medicine.

[76]  M. Pirmohamed,et al.  Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients , 2004, BMJ : British Medical Journal.

[77]  R. Rosenson,et al.  Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. , 2004, Endocrinology and metabolism clinics of North America.

[78]  J. Flier,et al.  Adipose Tissue as an Endocrine Organ , 2014 .

[79]  J. Tuomilehto,et al.  Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. , 2004, Archives of internal medicine.

[80]  R. Brook,et al.  Effect of short-term weight loss on the metabolic syndrome and conduit vascular endothelial function in overweight adults. , 2004, The American journal of cardiology.

[81]  A. Gotto,et al.  The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). , 2004, The American journal of cardiology.

[82]  S. Blair,et al.  Exercise capacity and body composition as predictors of mortality among men with diabetes. , 2004, Diabetes care.

[83]  P. Macfarlane,et al.  Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study , 2003, Circulation.

[84]  N. Poulter,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial☆ , 2003 .

[85]  L. Shaw,et al.  34th Bethesda Conference: Can atherosclerosis imaging techniques improve the detection of patients at risk for ischemic heart disease? , 2003 .

[86]  Allen J. Taylor,et al.  Executive summary—can atherosclerosis imaging techniques improve the detection of patients at risk for ischemic heart disease? , 2003 .

[87]  G. Reaven,et al.  Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. , 2003, The Journal of clinical endocrinology and metabolism.

[88]  Allen J. Taylor,et al.  34th Bethesda Conference: Executive summary--can atherosclerosis imaging techniques improve the detection of patients at risk for ischemic heart disease? , 2003, Journal of the American College of Cardiology.

[89]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[90]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[91]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[92]  W. Cromwell,et al.  Measurement issues related to lipoprotein heterogeneity. , 2002, The American journal of cardiology.

[93]  M. Nieminen,et al.  Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study , 2002, Journal of hypertension.

[94]  T. Buchanan,et al.  Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. , 2002, Diabetes.

[95]  P Hugh R Barrett,et al.  Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. , 2002, Diabetes.

[96]  S. Grundy,et al.  Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. , 2002, Archives of internal medicine.

[97]  James F Sallis,et al.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. , 2002, Circulation.

[98]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[99]  W. Dietz,et al.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.

[100]  U. P. S. T. Force,et al.  Measuring Quality: Are We Ready To Compare the Quality of Care among Physician Groups? , 2002, Annals of Internal Medicine.

[101]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[102]  S. Yusuf,et al.  Ramipril and the development of diabetes. , 2001, JAMA.

[103]  J. Hsia,et al.  Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. , 2001, The American journal of cardiology.

[104]  C. Bouchard,et al.  Effects of Endurance Exercise Training on Plasma HDL Cholesterol Levels Depend on Levels of Triglycerides: Evidence From Men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[105]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[106]  R. Blumenthal,et al.  ABCs of Cardiovascular Disease Risk Management , 2001, Cardiology in review.

[107]  Loyd,et al.  SIMVASTATIN AND NIACIN , ANTIOXIDANT VITAMINS , OR THE COMBINATION FOR THE PREVENTION OF CORONARY DISEASE , 2001 .

[108]  A. Aljada,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society The Suppressive Effect of Dietary Restriction and Weight Loss in the Obese on the Generation of Reactive Oxygen Species by Leukocytes, Lipid Per , 2022 .

[109]  Bezafibrate Infarction Prevention study Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.

[110]  W C Willett,et al.  A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. , 2000, The American journal of clinical nutrition.

[111]  G A Colditz,et al.  Walking compared with vigorous physical activity and risk of type 2 diabetes in women: a prospective study. , 1999, JAMA.

[112]  J. Vamecq,et al.  Medical significance of peroxisome proliferator-activated receptors , 1999, The Lancet.

[113]  M. de Lorgeril,et al.  Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. , 1999, Circulation.

[114]  S. Blair,et al.  Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men. , 1999, The American journal of clinical nutrition.

[115]  Jean-Louis Martin,et al.  Mediterranean Diet, Traditional Risk Factors, and the Rate of Cardiovascular Complications After Myocardial Infarction Final Report of the Lyon Diet Heart Study , 1999 .

[116]  G A Colditz,et al.  Abdominal adiposity and coronary heart disease in women. , 1998, JAMA.

[117]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[118]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[119]  D. Chisholm,et al.  The metabolically obese, normal-weight individual revisited. , 1998, Diabetes.

[120]  Vesa Manninen,et al.  Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study: Implications for Treatment , 1992, Circulation.

[121]  S. Haffner,et al.  Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? , 1990, JAMA.

[122]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[123]  J. Stamler,et al.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.